A national community-level study of Medicare patients with advanced non-small cell lung cancer found that adding targeted therapy to chemotherapy regimens was not cost-effective.
Rohan C. Parikh, MS
Advertisement
Articles by Rohan C. Parikh, MS
Advertisement
Latest Updated Articles
- Cost-Utility Analysis of Treatments for Advanced Non-Small Cell Lung Cancer
Published: January 6th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
3
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
4
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
5
